Similarly, cancer cells with hyperactivation of NRF2, which induces xCT expression, or loss of function of Kelch-like ECH-associated protein 1 (KEAP1), a negative regulator of NRF2, show a robust sensitivity to glutamine deprivation or glutaminase inhibition, in part through the increased glutamine export induced by high levels of xCT [74, 75]. The gene discussed is GLS; the disease is cancer.